Alector, Inc. ALEC
Alector, Inc. (Nasdaq: ALEC) is a CNS/neurology/psychiatry drug developer. Its lead program, AL137, is in Pre-clinical for Alzheimer's disease. Its next catalyst on record is GSK collaboration: Termination effective (January 2, 2027).
Upcoming catalysts
No catalyst is dated to the next 30 days or to an FDA action date.
Next further out: GSK collaboration — Termination effective (January 2, 2027). 3 catalysts on record beyond the next 30 days; subscribers see each with its filing sentence.
Pipeline
| Program | Indication | Modality | Stage |
|---|---|---|---|
| AL137 (anti-PyroGlu3 Abeta antibody + ABC) | Alzheimer's disease | antibody | Pre-clinical |
| AL064/AL164 (tau siRNA) | Alzheimer's disease and other tauopathies | RNA (siRNA/ASO/mRNA) | Pre-clinical |
| AL050 (GCase ERT + ABC) | Parkinson's disease / Lewy body dementia (GBA1) | protein/peptide | Pre-clinical |
| ADP062-ABC (alpha-synuclein siRNA) | Parkinson's disease | RNA (siRNA/ASO/mRNA) | Pre-clinical |
| ADP065-ABC (NLRP3 siRNA) | Multiple neurodegenerative conditions | RNA (siRNA/ASO/mRNA) | Pre-clinical |
Recent results and decisions
- Oct 15, 2026n/a Alector entered into an underwriting agreement to sell 36,600,000 shares of common stock at $2.05 per share for gross proceeds of approximately $75 million.
The gross proceeds from the Offering are expected to be $75,030,000.00 before deducting underwriting discounts and commissions and other offering expenses payable by the Company.
Filing - Oct 21, 2025missed INFRONT-3 Phase 3 missed the clinical co-primary endpoint (CDR plus NACC FTLD-SB); plasma progranulin co-primary was significant but no effect on secondary/exploratory biomarkers or vMRI; OLE and continuation study discontinued.
did not meet the clinical co-primary endpoint of slowing FTD-GRN progression
Filing
For subscribers
- Cash runway against each catalyst, with the company's own runway statement
- Track record: every Phase 3 readout, FDA decision and guidance slip since 2014
- Expected move for each dated catalyst, from comparable past events
- Phase 2 evidence behind each Phase 3 readout
- Companies on the same target or class
- Full catalyst list with filing sentences, deals, registered trials, Excel export
Other pre-clinical CNS/neurology/psychiatry companies
The free Monday brief
Last week's readouts and FDA decisions and the dated catalysts in the week ahead, each with its filing sentence.